GLP-1 · Weight loss · 2026
Semaglutide & tirzepatide
at NMPA-listed prices.
NMPA-approved GLP-1 medications for chronic weight management and type 2 diabetes — dispensed by Class A teaching-hospital pharmacies. Wegovy from $280/month, tirzepatide from $420/month. Bilingual prescription, physician’s letter for customs.
$280
Wegovy 2.4mg / month
vs ~$1,350 US list (~80% off)
NMPA-listed pricing
$420
Tirzepatide / month
10–15mg titration dose (~60% off US)
NMPA-listed pricing
14–17%
Avg loss on semaglutide
STEP-1 / STEP-5 at 68 weeks
NEJM 2021 / 2022
~21%
Avg loss on tirzepatide
SURMOUNT-1 at 72 weeks
NEJM 2022
NMPA
Wegovy approved 2024
Tirzepatide approved 2024
NMPA registry
Class A
Hospital pharmacy
Not back-channel sources
Standard at partner centres
Tiers & pricing
Six pathways, transparent pricing.
First-visit package
Endocrinology consult, baseline labs, ECG, contraindication screen, first month of medication, bilingual report.
$650–1,250
Refill / month
Hospital-pharmacy GLP-1 supply at NMPA-listed price. Optional remote check-in with prescribing endocrinologist.
$180–450
CGM run-in
Two-week continuous glucose monitor (Libre 3 / Dexcom G7) — useful for prediabetes and insulin-resistant phenotypes.
$180–280
Body composition
DEXA + indirect calorimetry baseline + 6-month re-test. Tracks lean mass through weight loss.
$250–400
Beinaglutide
Chinese-origin GLP-1, NMPA-indicated for obesity since 2023. 3x-daily injection.
$110–180 / month
Trial access
Mazdutide, HRS-7535 and other phase-3 multi-agonists in NMPA registry. Eligibility shortlist.
$450–950
Top centres
Where international patients
typically access GLP-1.
Shanghai Sixth People’s Hospital 上海第六人民医院
National reference for diabetes & obesity · Asia metabolic surgery flagship
Ruijin Hospital 瑞金医院
Class A teaching · strong endocrinology cohort · long-term outcomes data
Peking Union Medical College Hospital 北京协和医院
Diagnostic excellence · atypical phenotypes · multi-agonist trial site
China-Japan Friendship Hospital 中日友好医院
Class A · obesity MDT · cardiometabolic comorbidity workup
FAQ
GLP-1 in China — answered.
- Is semaglutide (Wegovy / Ozempic) available in China?
- Yes. Semaglutide was approved by NMPA for type 2 diabetes (Ozempic) in 2021 and for chronic weight management (Wegovy 2.4mg) in mid-2024. Both are imported from Novo Nordisk under licensed channels and dispensed by Class A hospital pharmacies. Indicative pricing: Ozempic 1mg pen ~$140 vs ~$900 US; Wegovy 2.4mg ~$280/month vs ~$1,350 US. Domestic biosimilars are in late-stage development and may launch in 2026–2027 at lower price points.
- Is tirzepatide (Mounjaro / Zepbound) available in China?
- Yes. Tirzepatide was approved by NMPA for type 2 diabetes in mid-2024 and for chronic weight management in late-2024 / early-2025. Indicative pricing: ~$420/month for the 10–15mg titration dose, vs ~$1,080/month US list. Supply has been periodically constrained globally; we confirm in-stock availability at the partner hospital pharmacy before quoting.
- Are there Chinese-origin GLP-1s?
- Yes — beinaglutide (贝那鲁肽, Benemae from Shanghai United Cell) is a domestic GLP-1 approved for T2D and is the only NMPA-approved GLP-1 explicitly indicated for obesity in adults with BMI ≥ 30 (or ≥ 27 with comorbidity) since 2023. It is a 3x-daily injection — pharmacokinetically less convenient than semaglutide — so for most international patients we still recommend semaglutide or tirzepatide. Several Chinese GLP-1 / GIP / glucagon multi-agonists are in phase 3 (mazdutide / IBI362 from Innovent; HRS-7535 from Hengrui) and may reach market 2026–2027.
- Who is eligible? What does the workup look like?
- Standard NMPA labels: chronic weight management for adults with BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, OSA, or known CV disease). For T2D: indicated regardless of BMI. Workup at the partner hospital: 30–45 minute endocrinology consult, baseline labs (HbA1c, fasting glucose, lipid panel, kidney/liver function, TSH, lipase, calcitonin if family history of MTC), ECG, contraindication screening (personal/family history of medullary thyroid carcinoma, MEN-2, severe gastroparesis, history of pancreatitis, current pregnancy/lactation). All-in workup: $300–550.
- What does it cost all-in?
- Indicative all-in pricing for an international patient on a 3-day visit: endocrinology consult + labs + ECG + first 1-month medication supply + bilingual report — semaglutide pathway $650–950; tirzepatide pathway $850–1,250. Refills: month-to-month at hospital-pharmacy pricing (sema ~$280, tirz ~$420). Add-ons: continuous glucose monitor (CGM) for two-week run-in $180–280; nutrition consult $80–150; metabolic phenotyping with DEXA + indirect calorimetry $250–400.
- Can I take medication home? For how long?
- Most countries permit personal-use import of a 90-day supply of non-controlled prescription medication in original labelled packaging accompanied by a physician’s letter. GLP-1s are non-controlled. We provide the bilingual prescription, English drug-info sheet, and an attending-physician letter for customs. Cold-chain considerations: pen devices are stable at 2–8°C unrefrigerated for up to 28 days (varies by product); for longer transport we provide an insulated cooling case. Continued therapy after the initial supply requires home-physician handover for prescription continuity.
- What outcomes can I expect?
- Average weight loss in NMPA-registry trials and Western phase-3 data: semaglutide 2.4mg ~14–17% body weight at 68 weeks (STEP-1, STEP-5 long-term); tirzepatide 15mg ~21% at 72 weeks (SURMOUNT-1). Individual response varies. Most loss occurs in months 3–12. Lifestyle (nutrition + resistance training) determines whether weight loss includes lean mass — we bundle a structured nutrition + exercise prescription and re-evaluate body composition at 6 and 12 months.
- What are the risks and contraindications?
- Most common: nausea, vomiting, constipation, diarrhoea — usually titration-dependent and improving over weeks. Less common but important: pancreatitis (stop drug, evaluate); gallbladder disease (rapid weight loss is a known cholelithiasis risk — we counsel on symptoms); severe gastroparesis worsening; rare reports of NAION (eye); hypoglycaemia if combined with sulfonylureas or insulin without dose reduction. Black-box contraindication: personal or family history of medullary thyroid carcinoma or MEN-2 — we screen on history and check baseline calcitonin if any family history. Pregnancy: stop ≥ 2 months before planned conception.
Related guides
All Weight-Loss Options
Compare medication, endoscopic and surgical paths and see which fits your BMI.
Read the guideDiabetes Care
T2D optimization, metabolic surgery and trial access at China’s reference centres.
Read the guideBariatric Surgery
Sleeve, RYGB, SADI-S for higher BMI or T2D remission.
Read the guideMedications Hub
All NMPA-approved drug pathways — browse by symptom.
Read the guideClinical Trials
Multi-agonist GLP-1 phase-3 trial access in China.
Read the guideReady for a written GLP-1 quote
in 48 hours?
Send your BMI, current medication, and any prior GLP-1 experience. We return a written workup-and-supply quote — including which hospital, which pen size, and what the month-2 to month-12 maintenance cost looks like.
For information only. Not medical advice. GLP-1 prescription decisions must be made with a licensed clinician based on your individual circumstances and contraindications. We do not guarantee any specific weight-loss outcome.